# Pfizer Inc. (PFE) - Earnings Validation Framework

**Posición:** €500 (5% portfolio), 20 shares @ $25.65 USD
**Earnings Date:** Feb 3, 2026 (Q4 2025, estimado - confirmar fecha exacta)
**Thesis Original:** thesis/research/PFE/thesis.md

---

## Thesis Summary

**Core thesis:**
- Big pharma US atravesando transición post-COVID difícil
- **Yield 6.84% EXTREMO** para big pharma = cushion defensivo downside
- P/E 14.8x (22% bajo histórico 19x), forward P/E 8.81x = barato prospectivo
- Pipeline obesity (Metsera GLP-1) + oncology ADCs para reponer patent cliff $17-18B
- Balance sólido Debt/Eq 0.67x, FCF $12.4B robusto
- Margen seguridad 25-35% si pipeline ejecuta medianamente

**Key risks:**
- Patent cliff 2026-28: Prevnar 13, Eliquis Medicare negotiation, Ibrance/Xtandi LOE
- Pipeline execution: Obesity unproven, ADCs early stage
- Revenue decline 2026-27 si pipeline falla
- Moat erosionando temporalmente (se reconstruye si pipeline funciona)

**Valuation:**
- Fair value: $32-38 (margen seguridad 25-48%)
- Yield 6.84% compensa downside mientras se resuelve transición

---

## Métricas Críticas a Verificar (Q4 2025)

### 1. Earnings Quality - Q4 2025

| Métrica | Target Thesis | Threshold HOLD | Threshold CONCERN |
|---------|--------------|----------------|-------------------|
| **Revenue Q4** | $16-17B | ≥$15.5B ✅ | <$15B ⚠️ |
| **EPS adjusted** | $0.60-0.70 | ≥$0.55 ✅ | <$0.50 ⚠️ |
| **FCF Q4** | $3-4B | ≥$2.5B ✅ | <$2B ⚠️ |
| **Guidance FY2026 revenue** | $59.5-62.5B | ≥$58B ✅ | <$58B ⚠️ |
| **Guidance FY2026 EPS** | $2.80-3.00 | ≥$2.70 ✅ | <$2.60 ⚠️ |

**Context:** 2025E revenue $62B, Q4 debe confirmar transición post-COVID completa.

### 2. Pipeline Progress - CRÍTICO

| Programa | Validate ✅ | Flag ⚠️ | CONCERN ❌ |
|----------|------------|---------|------------|
| **Metsera GLP-1 obesity** | Phase 2 data positiva Q4/Q1 | Phase 2 delayed | Phase 2 failed/discontinued |
| **ADCs oncology** | 1+ programa Phase 3 advancing | No progress | 1+ programa discontinued |
| **Eliquis Medicare impact** | Price cut <30% confirmed | Cut 30-40% | Cut >40% |
| **Prevnar 20 uptake** | Q4 sales $1.3-1.5B | Sales <$1.2B | Competitive loss |

**Critical:** Obesity pipeline es BET principal para reponer patent cliff. Si Metsera falla, thesis weakens significativamente.

### 3. Dividend Sustainability - CORE DEFENSIVE THESIS

| Check | HOLD ✅ | CONCERN ⚠️ | SELL SIGNAL ❌ |
|-------|---------|------------|----------------|
| **Dividend maintained** | $1.72/share confirmed | - | CUT announced |
| **Payout ratio** | <80% | 80-90% | >90% |
| **FCF covers dividend** | FCF >$12B, dividend $10.3B | FCF $10-12B | FCF <$10B |
| **Guidance 2026 dividend** | Maintained or raised | Flat | Cut guidance |

**CRITICAL:** Yield 6.84% es 50% de la thesis defensiva. Si dividend cortado → thesis INVALIDADA.

### 4. Patent Cliff Mitigation - Execution

| Item | On Track ✅ | Delayed ⚠️ | Failed ❌ |
|------|-------------|------------|-----------|
| **Cost restructuring** | $4B savings program on track | Behind target | Abandoned |
| **R&D productivity** | 2+ readouts positivos Q4 | 0-1 readouts | Multiple failures |
| **M&A pipeline fill** | 1+ acquisition announced/rumored | No activity | Overpaid acquisition |

---

## Triggers de Decisión Post-Earnings

### ACCIÓN: HOLD (más probable)

**Condiciones:**
- ✅ Q4 earnings meet guidance ($16-17B revenue, EPS $0.60-0.70)
- ✅ FY2026 guidance reconfirmed $59.5-62.5B revenue
- ✅ Pipeline progress: Metsera advancing, ADCs on track
- ✅ Dividend $1.72 maintained, payout <80%
- ✅ FCF $12B+ confirms sustainability

**Razonamiento:**
- Thesis intacta: Transición progressing as expected
- Yield 6.84% cushion vale la pena mientras pipeline se resuelve
- Margen 25-35% apropiado para execution risk
- Menos riesgo que Sanofi (pipeline más diverso, balance mejor)

**Portfolio impact:** Defensive 15% mantiene (Pfizer 5%)

---

### ACCIÓN: ADD €200-300 (5% → 7-8% total)

**Condiciones:**
- ✅ Q4 earnings BEAT guidance (revenue >$17.5B, EPS >$0.75)
- ✅ FY2026 guidance RAISED >$63B revenue
- ✅ Metsera GLP-1 Phase 2 data POSITIVA (weight loss >15%, safety OK)
- ✅ Dividend RAISED $1.80+ OR special dividend announced
- ✅ Stock reaction muted (yield aumenta a 7%+ post-earnings)

**Razonamiento:**
- Pipeline derisking significantly
- Obesity thesis validating = upside $40+ si funciona
- Yield >7% = compelling risk/reward
- Defensive gap cierre: 15% → 17-18%

**Portfolio impact:**
- Defensive: 15% → 17-18%
- Pharma sector: 5% → 7-8% (OK <10%)
- Cash post-ADD: €5,500 (55%) OK

**Risk:** Aumenta concentración pharma, pero upside justifica si pipeline valida.

---

### ACCIÓN: TRIM 40-50% (€500 → €250-300)

**Condiciones:**
- ⚠️ Q4 earnings MISS (revenue <$15.5B, EPS <$0.55)
- ⚠️ FY2026 guidance CUT <$59B revenue
- ⚠️ Pipeline: Metsera delayed O 1+ ADC discontinued
- ⚠️ Eliquis Medicare cut >35% (vs expectation 25-30%)
- ⚠️ FCF <$11B (stressing dividend coverage)

**Razonamiento:**
- Thesis weakening: Patent cliff impact peor que esperado
- Pipeline no compensating fast enough
- Reduce exposure PERO mantiene yield 6.84% parcialmente
- Libera €200-250 para mejores oportunidades defensive

**Portfolio impact:**
- Defensive: 15% → 12-13%
- Cash: 58% → 60%

**Siguiente:** Re-evaluar Q1 2026 earnings antes de exit completo

---

### ACCIÓN: SELL 100% (€500 out) - Unlikely pero posible

**Condiciones (al menos 2-3):**
- ❌ **DIVIDEND CUT** <$1.50 (DEALBREAKER #1)
- ❌ Q4 earnings disaster (revenue <$14B, EPS <$0.40)
- ❌ FY2026 guidance catastrophic cut <$56B
- ❌ Metsera GLP-1 Phase 2 FAILED + 2+ ADCs discontinued
- ❌ FCF <$10B (dividend unsustainable)
- ❌ Debt/Equity >1.0x (balance deteriorating)

**Razonamiento:**
- Thesis INVALIDADA: Yield trap (dividend cortado = 50% thesis gone)
- Pipeline failure = no path to revenue growth 2027+
- Mejor alternativa: Sanofi watchlist (margen 20-25%, pipeline diferente)

**Capital reallocation:**
- €500 → Cash (esperar oportunidades)
- O → Sanofi si precio €70-75 (margen 30%+)
- O → Utilities EM si aparece value

---

## Comparación Competitiva Post-Earnings

**Si Pfizer earnings OK, comparar vs peers big pharma:**

| Métrica | Pfizer | Eli Lilly | Merck | J&J | Better |
|---------|--------|-----------|-------|-----|--------|
| **P/E** | 14.8x | 40x+ | 15x | 16x | PFE ✅ |
| **Yield** | 6.84% | 0.7% | 3.0% | 3.1% | PFE ✅✅ |
| **Pipeline obesity** | Metsera (early) | Mounjaro/Zepbound (líder) | - | - | LLY ✅ |
| **Patent cliff** | 2026-28 $17B | Minimal | Keytruda 2028 | Minimal | Others ✅ |
| **Balance** | Debt/Eq 0.67x | Similar | Similar | Lower | All OK |

**Conclusión:**
- Pfizer **value claro** (yield 6.84%, P/E 14.8x) vs peers
- Pipeline obesity INFERIOR Eli Lilly PERO Pfizer 1/3 del precio
- Si Metsera funciona → re-rate brutal hacia $40+
- Si Metsera falla → yield 6.84% cushion vs downside

**Decisión:** Pfizer es mejor value pharma SI dividend sostenible. Lilly mejor growth PERO overvalued.

---

## Checklist Post-Earnings (Feb 3)

**Inmediatamente después earnings release:**

- [ ] Leer earnings release + guidance FY2026
- [ ] Verificar métricas críticas tabla arriba
- [ ] Buscar pipeline updates (Metsera, ADCs) específicamente
- [ ] Verificar dividend confirmed $1.72 (CRITICAL)
- [ ] Leer management commentary sobre patent cliff mitigation

**Earnings call (same day o +1):**

- [ ] Escuchar earnings call (o leer transcript)
- [ ] Q&A sobre Metsera GLP-1 timing + data
- [ ] Q&A sobre Eliquis Medicare negotiation impact
- [ ] Q&A sobre dividend sustainability + payout policy

**Análisis (1-2 días post):**

- [ ] Verificar reacción mercado + yield post-earnings
- [ ] Leer 3-5 analyst notes (focus pipeline commentary)
- [ ] Comparar guidance vs consensus (beat/meet/miss)
- [ ] Actualizar thesis/research/PFE/thesis.md
- [ ] Decidir acción: HOLD / ADD / TRIM / SELL

**Si decisión = ADD o SELL:**

- [ ] Ejecutar operación en eToro
- [ ] Actualizar portfolio/current.yaml
- [ ] Calcular impacto defensive % (15% → 17-18% si ADD, → 12% si TRIM)
- [ ] Informar usuario con resumen ejecutivo

---

## Contexto Macro Relevante

**Pharma sector:**
- Medicare negotiation 2026: Eliquis en lista, cut esperado 25-35%
- GLP-1 obesity market: Lilly/Novo líderes, Pfizer late entrant
- Patent cliff industry-wide: Múltiples big pharma enfrentando LOE 2026-28

**Defensive context:**
- Portfolio gap defensive 20-25% (Pfizer 5% de 35-40% target)
- Yield 6.84% top defensive asset portfolio
- Si Pfizer falla → buscar replacement yield similar (difícil)

**Pipeline context:**
- Metsera GLP-1: Acquired Metsera $680M upfront 2024, Phase 2 data expected Q4 2025/Q1 2026
- ADCs oncology: Multiple programs Phase 1-2, market hot (competitors valuing ADCs highly)
- Success rate: Phase 2 → approval = 30-40% pharma, obesity specific higher ~50%

---

**PREPARED:** 2026-01-30
**NEXT REVIEW:** Post-earnings Feb 3, 2026
**DECISION DEADLINE:** Feb 5 (antes de Allstate/Shell earnings)
**CRITICAL WATCH:** Dividend announcement (DEALBREAKER si cortado)